Format

Send to

Choose Destination
Indian J Med Ethics. 2017 Apr-Jun;2(2):82-88.

Lessons learnt in Japan from adverse reactions to the HPV vaccine: a medical ethics perspective.

Author information

1
Administrative Director of NPO DIPEx-Japan, Yokohama SOWA Clinic, Physician, Kanagawa, Japan,. hibep@nifty.com.
2
Attorney at law, Santama Law Firm, Secretary-General, Medwatcher Japan, Tokyo, Japan,. minaguchi@san-tama.com.
3
Special Professor, Health Information Management Stage, Komatsu College, Ishikawa, Japan,. uchide@komatsu-c.ac.jp.
4
Professor, Department of Mass Communication, College of Media and Communication, Edogawa University, Chiba, Japan,. kuma@edogawa-u.ac.jp.
5
Attorney at Law, Kashinoki Law Firm, Tokyo, Japan,. seki.kashinoki@nifty.com.
6
Associate Professor, Nursing Statistics, Graduate School of Nursing Science, St. Luke's International University, Tokyo, Japan,. y-yaju@slcn.ac.jp.

Abstract

The human papillomavirus (HPV) vaccine has been linked to a number of serious adverse reactions. The range of symptoms is diverse and they develop in a multi-layered manner over an extended period of time. The argument for the safety and effectiveness of the HPV vaccine overlooks the following flaws: (i) no consideration is given to the genetic basis of autoimmune diseases, and arguments that do not take this into account cannot assure the safety of the vaccine; (ii) the immune evasion mechanisms of HPV, which require the HPV vaccine to maintain an extraordinarily high antibody level for a long period of time for it to be effective, are disregarded; and (iii) the limitations of effectiveness of the vaccine. We also discuss various issues that came up in the course of developing, promoting and distributing the vaccine, as well as the pitfalls encountered in monitoring adverse events and epidemiological verification.

[Indexed for MEDLINE]

Supplemental Content

Loading ...
Support Center